2026 is shaping up to be a key year for Isomorphic Labs, the Alphabet spinoff focused on computational drug design. The company recently signed Merck as its latest partner, agreeing to use Merck datasets in its IsoDDE engine to find small molecules for a single oncology target. This announcement came two days after Isomorphic closed a $5 billion Series C round. The deal also includes an upfront payment and potential milestone payments or royalties on net sales.
Advancing the IsoDDE System
Isomorphic unveiled its IsoDDE system in February, claiming it goes beyond AlphaFold 3 by predicting not just protein structure but also how strongly a drug binds to its target. For this oncology project, Isomorphic will run predictions in IsoDDE and deliver molecular designs. The company’s own benchmarking shows IsoDDE more than doubles the accuracy of AlphaFold 3 on the hardest protein-ligand cases in the Runs N’ Poses benchmark.
Isomorphic began working with Lilly and Novartis in January 2024 to find small molecules for multiple targets. Novartis expanded its agreement in February 2025 to add up to three research programs. Merck, known as MSD outside the U.S. and Canada, will handle preclinical and clinical development, as well as manufacturing and marketing. “The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions,” said George Addona, head of discovery, preclinical development and translational medicine at Merck Research Laboratories.
Isomorphic also plans to use the new capital to advance internal programs, which have reported positive preclinical results in oncology and immunology. These efforts are described as “deep in pre-clinical development” by President Max Jaderberg. Isomorphic raised a $2.1 billion Series B in May. In the top 20 drugmakers’ 2025 AI drug discovery deals, about 2% of $29.5 billion in headline value was paid up front, McKinsey found.
